[go: up one dir, main page]

AU8392998A - (pseudomonas) exotoxin a-like chimeric immunogens for eliciting a secreto ry iga-mediated immune response - Google Patents

(pseudomonas) exotoxin a-like chimeric immunogens for eliciting a secreto ry iga-mediated immune response

Info

Publication number
AU8392998A
AU8392998A AU83929/98A AU8392998A AU8392998A AU 8392998 A AU8392998 A AU 8392998A AU 83929/98 A AU83929/98 A AU 83929/98A AU 8392998 A AU8392998 A AU 8392998A AU 8392998 A AU8392998 A AU 8392998A
Authority
AU
Australia
Prior art keywords
iga
eliciting
immune response
mediated immune
exotoxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU83929/98A
Inventor
David J. Fitzgerald
Randall J. Mrsny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
US Department of Health and Human Services
Original Assignee
Genentech Inc
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, US Department of Health and Human Services filed Critical Genentech Inc
Publication of AU8392998A publication Critical patent/AU8392998A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C03—GLASS; MINERAL OR SLAG WOOL
    • C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
    • C03C1/00—Ingredients generally applicable to manufacture of glasses, glazes, or vitreous enamels
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C23—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
    • C23C—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL
    • C23C22/00—Chemical surface treatment of metallic material by reaction of the surface with a reactive liquid, leaving reaction products of surface material in the coating, e.g. conversion coatings, passivation of metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Geochemistry & Mineralogy (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Mechanical Engineering (AREA)
  • Metallurgy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

This invention provides methods of eliciting a secretry IgA-mediated immune response in a subject by administering a Pseudomonas exotoxin A-like chimeric immunogens that include a non-native epitope in the Ib domain of Pseudomonas exotoxin. Compositions comprising secretory IgA antibodies that specifically recognize an epitope of HIV-1 also are provided.
AU83929/98A 1997-07-11 1998-07-10 (pseudomonas) exotoxin a-like chimeric immunogens for eliciting a secreto ry iga-mediated immune response Abandoned AU8392998A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5692497P 1997-07-11 1997-07-11
US60056924 1997-07-11
PCT/US1998/014336 WO1999002712A1 (en) 1997-07-11 1998-07-10 Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response

Publications (1)

Publication Number Publication Date
AU8392998A true AU8392998A (en) 1999-02-08

Family

ID=22007394

Family Applications (1)

Application Number Title Priority Date Filing Date
AU83929/98A Abandoned AU8392998A (en) 1997-07-11 1998-07-10 (pseudomonas) exotoxin a-like chimeric immunogens for eliciting a secreto ry iga-mediated immune response

Country Status (6)

Country Link
EP (1) EP1000162B1 (en)
AT (1) ATE340863T1 (en)
AU (1) AU8392998A (en)
DE (1) DE69836024T2 (en)
ES (1) ES2274573T3 (en)
WO (1) WO1999002712A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2802426B1 (en) * 1999-12-15 2004-04-02 Neovacs USE OF IMMUNOSUPPRESSIVE AND / OR ANGIOGENIC IMMUNOGENIC PROTEINS MADE INACTIVE FOR THE PRODUCTION OF SECRETORY IGAs
US20030049689A1 (en) * 2000-12-14 2003-03-13 Cynthia Edwards Multifunctional polypeptides
JP2004528018A (en) 2000-12-21 2004-09-16 アメリカ合衆国 Chimeric proteins containing non-toxic Pseudomonas exotoxin A and type IV pilin sequences
WO2006041906A2 (en) 2004-10-04 2006-04-20 Trinity Biosystems, Inc. Methods and compositions for immunizing against pseudomonas infection
WO2006050420A2 (en) * 2004-11-01 2006-05-11 Trinity Biosystems, Inc. Chimeric immunogens that comprise ovalbumin
WO2006125076A2 (en) 2005-05-18 2006-11-23 Trinity Biosystems, Inc. Methods and compositions for immunizing against chlamydia infection
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
PL3762009T3 (en) 2018-03-08 2022-09-12 Applied Molecular Transport Inc. Toxin-derived delivery constructs for oral delivery
BR112021009001A8 (en) 2018-11-07 2021-10-26 Applied Molecular Transport Inc Cholix-derived vehicles for oral delivery of heterologous payload

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05502880A (en) * 1989-12-22 1993-05-20 セラジェン・インコーポレーテッド Hybrid molecule with a translocation region and a cell binding region
US5573916A (en) * 1994-05-19 1996-11-12 Coretech, Inc. Immunogenic constructs comprising b-cell and t-cell epitopes on common carrier
JP2001504334A (en) * 1996-11-06 2001-04-03 アメリカ合衆国 Protease-activatable Pseudomonas exotoxin A-like proprotein

Also Published As

Publication number Publication date
WO1999002712A1 (en) 1999-01-21
DE69836024T2 (en) 2007-09-27
EP1000162A1 (en) 2000-05-17
ATE340863T1 (en) 2006-10-15
DE69836024D1 (en) 2006-11-09
EP1000162B1 (en) 2006-09-27
ES2274573T3 (en) 2007-05-16

Similar Documents

Publication Publication Date Title
WO1994019466A3 (en) A novel family of anti-carcinoembryonic antigen chimeric antibodies
WO1999006544A8 (en) Membrane-bound cytokine compositions and methods of modulating an immune response using same
GEP20105119B (en) Chimeric anti-cd20 antibody
IL132249A0 (en) Type ii tgf-beta receptor/immunoglobulin constant region fusion proteins
WO1994029451A3 (en) Humanised antibodies
AU3117201A (en) Methods and compositions for generating human monoclonal antibodies
EP1198250B8 (en) Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
EP0757099A3 (en) CTLA4 mutant molecules and uses thereof
AU8083594A (en) Synthetic human neutralizing monoclonal antibodies to human immunodeficiency virus
EP0677533A3 (en) Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
WO2001070984A3 (en) Anti-tissue factor antibodies with enhanced anticoagulant potency
WO2002081646A3 (en) Epitope sequences
AU8817391A (en) Method for the production of antibodies
WO2001081609A3 (en) Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
AU8392998A (en) (pseudomonas) exotoxin a-like chimeric immunogens for eliciting a secreto ry iga-mediated immune response
WO1996020277A3 (en) Recombinant monoclonal anti-idiotype antibody 3h1 sequences relating to human carcinoembryonic antigen
DK1000163T3 (en) Pseudomonas exotoxin A-like chimeric immunogens
AU5242296A (en) Anti-idiotypic antibodies which induce an immune response against epidermal growth factor receptor
NO972522L (en) Monoclonal antibodies with immunosuppressive activity
DK0831881T3 (en) CETP to increase HDL cholesterol levels
WO1992004464A3 (en) Monoclonal antibodies against tenascin
AU4537100A (en) Adjuvant combinations for immunization composition and vaccines
WO2003097663A3 (en) Immunogenic, monoclonal antibody comprising at least 2 different epitopes of a tumor-associated antigen
WO2001092307A3 (en) Therapeutic compounds for ovarian cancer
GR3031255T3 (en) A novel endothelial cell molecule mediating lymphocyte binding in man.

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase